Gastrointestinal Cancer
News
Selective resection feasible for esophageal cancer
Major finding: Five-year survival rates after definitive chemoradiotherapy were 53% with complete clinical responses to definitive...
News
Racial gap in gastric cancer survival narrows at 3 years
Major Finding: Three-year relative conditional survival rates for Asian, black, or white patients with gastric cancer who underwent curative...
News
Capecitabine chemoradiotherapy effective in local pancreatic cancer
Major Finding: Median progression-free survival after 9 months of follow-up was 12 months in 35 patients given capecitabine plus radiotherapy...
News
Survival shorter in young gastric cancer patients
Major Finding: Patients diagnosed with gastric adenocarcinoma before age 40 years lived a median of 5 months; older patients lived a median of 8...
News
Screen asymptomatic siblings of CRC patients
Major Finding: The prevalence of advanced colorectal neoplasms was approximately three times higher among siblings of colorectal cancer patients (...
Conference Coverage
Gene profiling predicted responses to colorectal, pancreatic cancer treatment
Major finding: Gene expression patterns identified three subtypes of stage II or III colorectal cancer with different responses to 5-FU–based...
News
Japanese study: S-1 adjuvant chemo improved pancreatic cancer survival
Major Finding: 2-year survival rates for Japanese patients who underwent resection of pancreatic cancer were 70% for those receiving postoperative...
Conference Coverage
Add-on nab-paclitaxel extends survival in metastatic pancreatic cancer
Major Finding: Median overall survival in patients with metastatic pancreatic cancer increased from 6.7 months on gemcitabine to 8.5 months on nab...
News
Obesity, diabetes fuel liver disease epidemic
News
Statins may reduce mortality in hepatocellular cancer
Major finding: Patients with hepatocellular cancer showed significantly improved median survival if they were on statins (22 months) compared with...
News
Bevacizumab boosts capecitabine response in elderly with metastatic colorectal cancer
Major Finding: Progression-free survival improved from 5.1 months on capecitabine to 9.1 months on capecitabine plus bevacizumab in elderly...